Atlantic Private Wealth’s Denali Therapeutics DNLI Stock Holding History

Atlantic Private Wealth’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$192	Hold	10	–	–	﹤0.01%	310
2025 Q4	$165	Buy	+10	New	+$169	﹤0.01%	389

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Atlantic Private Wealth's DNLI Position: Q1 2026 in Review

Atlantic Private Wealth held its Denali Therapeutics (DNLI) position steady in Q1 2026 at 10 shares worth $192. The position accounts for ﹤0.01% of the portfolio, ranked #310.

Atlantic Private Wealth first reported a position in DNLI in Q4 2025 and has held it in 2 quarters since. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Atlantic Private Wealth held 10 shares of Denali Therapeutics worth $192 as of Q1 2026.
Atlantic Private Wealth left its Denali Therapeutics share count unchanged in Q1 2026.
Denali Therapeutics made up ﹤0.01% of Atlantic Private Wealth's portfolio in Q1 2026, its #310 holding.
Atlantic Private Wealth first reported a position in Denali Therapeutics in Q4 2025 and has held it in 2 quarters since.
268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Atlantic Private Wealth's 13F filing for Q1 2026, filed 8 May 2026.